


Figure S11



Supplementary information, Figure S11 EGFR inhibition resensitizes *SMARCE1* deficient EBC1 NSCLC cells to MET inhibitor.

EBC1 NSCLC cells (MET amplified) expressing pRS control or sh*SMARCE1* vectors were cultured in the absence and presence of 50 nM crizotinib, 500 nM gefitinib, or the combination of 1 μ M 50 nM crizotinib and 500 nM gefitinib. The cells were fixed, stained and photographed after 10 (untreated and gefitinib alone) or 32 days (crizotinib alone and gefitinib plus crizotinib).